CN116462675A - 一种小檗碱衍生物及其制备方法和应用 - Google Patents
一种小檗碱衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116462675A CN116462675A CN202310513482.XA CN202310513482A CN116462675A CN 116462675 A CN116462675 A CN 116462675A CN 202310513482 A CN202310513482 A CN 202310513482A CN 116462675 A CN116462675 A CN 116462675A
- Authority
- CN
- China
- Prior art keywords
- berberine
- compound
- preparation
- berberine derivative
- test tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003832 berberine derivatives Chemical class 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 9
- 229940124350 antibacterial drug Drugs 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 11
- 229940093265 berberine Drugs 0.000 description 11
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 11
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 235000015278 beef Nutrition 0.000 description 7
- 239000012137 tryptone Substances 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 4
- 241001225321 Aspergillus fumigatus Species 0.000 description 3
- 241001465318 Aspergillus terreus Species 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000235645 Pichia kudriavzevii Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- -1 stirred Chemical compound 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一种小檗碱衍生物及其制备方法和应用。本发明的小檗碱衍生物具有好的抗菌活性,可用于抗菌药物中的用途。本发明公开了其制法。
Description
技术领域
本发明涉及一种小檗碱衍生物,及其在制药中的应用,属于医药技术领域。
背景技术
小檗碱具有抗菌作用,它对白色念珠菌、热带假丝酵母、鲁希特念珠菌、克柔念珠菌、烟曲霉、土曲霉及隐球菌等具有较好的抑制作用;但其水溶性和脂溶性较差,使其不易被有效的输送至细胞内和患病部位,导致生物利用度低;为克服小檗碱的缺陷、提高小檗碱的生物活性,小檗碱及其衍生物的研究和开发非常活跃。
已有的研究结果表明,将小檗碱8-位引入小于8个碳原子的烷基,随着碳原子数目的增加,抗菌活性增强;在小檗碱9-位引入含有长链烷基的取代基或苄基取代的苯并咪唑基团,可以提高小檗碱的抗菌活性;将小檗碱1-位与13位通过乙烯基连接形成环化小檗碱,可提高化合物的抗耐甲氧西林金黄色葡萄球菌的活性。
本发明在8-氯小檗碱(制备方法参考Molla Endeshaw,et al,8,8-Dialkyldihydroberberines with Potent Antiprotozoal Activity,Journal ofNatural Products, 2013, 76, 311−315)结构中引入具有抗菌作用的长链烷氨基二硫代甲酸结构,对小檗碱进行修饰和改造,以期获得抗菌活性较好的小檗碱衍生物。
发明内容
本发明的目的在于提供一种小檗碱衍生物,其具有抗菌作用。
本发明的另一目的在于提供上述小檗碱衍生物的制备方法。
本发明的再一目的在于提供上述小檗碱衍生物的抗菌用途。
以下对本发明进行详细描述。
本发明提供的小檗碱衍生物,具有如下通式:
式中,R各自独立为C6H13 , C8H17 , C12H25 , C4H9 , C3H7 , C2H5 , CH2C6H5, 。
所述的小檗碱衍生物具体代表实例结构式如下:
本发明还提供了上述化合物的制备方法:
式中,R各自独立为C6H13 , C8H17 , C12H25 , C4H9 , C3H7 , C2H5 , CH2C6H5, ;B各自独立为Et3N,吡啶。
本发明的小檗碱衍生物,在制备抗菌药物中的应用。
通过以下实施例进一步举例说明本发明,但应注意本发明的范围并不受这些实施例的任何限制。
实施方式
实施例
小檗碱衍生物的制备
将二硫化碳0.84g(11mmol)加入到50mL甲苯中,搅拌,加入RNH2(10 mmol)、Et3N1.11g(11 mmol)或吡啶0.869g(11 mmol),室温反应2-3h,得到N-烷氨基二硫代甲酸盐(I)甲苯溶液,不经纯化直接用于下步反应。
将8-氯小檗碱(II)4.06g (10 mmol)加入50mL甲苯中,搅拌,慢慢加入上述N-烷氨基二硫代甲酸盐(I)(11 mmol)的甲苯溶液,35-45℃反应至完全,倾入100mL0.5%的碳酸钠溶液中,搅拌,静置分层,水相甲苯萃取,无水硫酸钠干燥,过滤,减压蒸干,回收溶剂,硅胶柱层析纯化(V二氯甲烷:V甲醇= 40:1),分别制得化合物(1)-(8)。
化合物(1): 收率79.2%;ESI-MS (m/z): 511.1 [M-Cl]+;1HNMR (400MHz, DMSO-d6) δ (ppm):8.77 (s, 1H), 7.71 (d, J= 9.1Hz, 1H), 7.65 (d, J= 9.1Hz, 1H),7.24 (s, 1H), 6.90 (s, 1H), 6.18 (s, 2H), 5.12 (m, 2H), 4.38 (s, 3H), 4.09(s, 3H), 3.31 (m, 2H), 3.15 (m, 2H), 1.76 (m, 2H), 1.33-1.29 (m, 6H), 0.96(t, J= 6.7Hz, 3H)。
化合物(2): 收率78.6%;ESI-MS (m/z): 539.2 [M-Cl]+;1HNMR (400MHz, DMSO-d6) δ (ppm):8.78 (s, 1H), 7.72 (d, J= 9.0Hz, 1H), 7.66 (d, J= 9.0Hz, 1H),7.25 (s, 1H), 6.90 (s, 1H), 6.19 (s, 2H), 5.14 (m, 2H), 4.39 (s, 3H), 4.10(s, 3H), 3.33 (m, 2H), 3.17 (m, 2H), 1.69 (m, 2H), 1.30-1.29 (m, 10H), 0.96(t, J= 6.6Hz, 3H)。
化合物(3): 收率77.7%;ESI-MS (m/z): 595.2 [M-Cl]+;1H NMR (400MHz, DMSO-d6) δ (ppm):8.79 (s, 1H), 7.73 (d, J= 9.5Hz, 1H), 7.67 (d, J= 9.5Hz, 1H),7.26 (s, 1H), 6.91 (s, 1H), 6.19 (s, 2H), 5.15 (m, 2H), 4.39 (s, 3H), 4.10(s, 3H), 3.32 (m, 2H), 3.19 (m, 2H), 1.59 (m, 2H), 1.33-1.29 (m, 18H), 0.97(t, J= 6.7Hz, 3H)。
化合物(4): 收率74.8%;ESI-MS (m/z): 483.1 [M-Cl]+;1H NMR (400MHz, DMSO-d6) δ (ppm):8.76 (s, 1H), 7.70 (d, J= 9.1Hz, 1H), 7.63 (d, J= 9.1Hz, 1H),7.24 (s, 1H), 6.89 (s, 1H), 6.17 (s, 2H), 5.12 (m, 2H), 4.38 (s, 3H), 4.09(s, 3H), 3.31 (m, 2H), 3.22 (m, 2H), 1.67 (m, 2H), 1.33-1.29 (m, 2H), 0.98(t, J= 6.7Hz, 3H)。
化合物(5): 收率74.1%;ESI-MS (m/z): 469.1 [M-Cl]+;1H NMR (400MHz, DMSO-d6) δ (ppm):8.75 (s, 1H), 7.70 (d, J= 9.1Hz, 1H), 7.62 (d, J= 9.1Hz, 1H),7.23 (s, 1H), 6.89 (s, 1H), 6.16 (s, 2H), 5.11 (m, 2H), 4.36 (s, 3H), 4.08(s, 3H), 3.31 (m, 2H), 3.20 (m, 2H), 1.67 (m, 2H), 0.99 (t, J= 6.7Hz, 3H)。
化合物(6): 收率77.3%;ESI-MS (m/z): 455.1 [M-Cl]+;1H NMR (400MHz, DMSO-d6) δ (ppm):8.74 (s, 1H), 7.69 (d, J= 9.1Hz, 1H), 7.62 (d, J= 9.1Hz, 1H),7.22 (s, 1H), 6.88 (s, 1H), 6.16 (s, 2H), 5.10 (m, 2H), 4.36 (s, 3H), 4.06(s, 3H), 3.22 (m, 2H), 3.28 (m, 2H), 1.67 (t, J= 6.7Hz, 3H)。
化合物(7): 收率73.6%;ESI-MS (m/z): 517.1 [M-Cl]+;1H NMR (400MHz, DMSO-d6) δ (ppm):8.77 (s, 1H), 7.70 (d, J= 9.1Hz, 1H), 7.63 (d, J= 9.1Hz, 1H),7.52-7.27 (m, 5H),7.24 (s, 1H), 6.92 (s, 1H), 6.17 (s, 2H), 5.11 (m, 2H),4.35 (s, 3H), 4.06 (s, 3H), 3.89 (m, 2H), 3.30 (m, 2H),。
化合物(8): 收率79.0%;ESI-MS (m/z): 561.1 [M-Cl]+;1H NMR (400MHz, DMSO-d6) δ (ppm):8.80 (s, 1H), 7.72 (d, J= 9.0Hz, 1H), 7.65 (d, J= 9.0Hz, 1H),7.26 (s, 1H), 6.94 (s, 1H), 6.18 (s, 2H), 5.14 (m, 2H), 4.37 (s, 3H), 4.10(s, 3H), 3.90 (m, 2H), 3.33 (m, 2H), 2.35 (m, 9H)。
实施例
小檗碱衍生物的抗菌活性
配置牛肉膏胰蛋白胨培养基(每100mL培养基含牛肉膏0.3g,胰蛋白胨1g,氯化钠0.5g,琼脂2g,蒸馏水100mL),于121℃,0.1MPa下高压蒸汽灭菌0.5h,取无菌试管12个,1-12编号;1号试管加入8mL牛肉膏胰蛋白胨培养基,其余每个试管加入5mL牛肉膏胰蛋白胨培养基;在1号试管中加入浓度为1280μg/mL的化合物(1)2mL,混匀后从1号试管中吸取化合物(1)与牛肉膏胰蛋白胨培养基的混合液5mL至2号试管,混匀后再从2号试管中吸取5mL化合物(1)与牛肉膏胰蛋白胨培养基的混合液5mL至3号试管,如此倍比稀释至11号试管,并从11号试管中吸取化合物(1)与牛肉膏胰蛋白胨培养基的混合液5mL弃去;12号试管为不含化合物(1)的空白培养基对照。此时,1-11号试管中化合物(1)的浓度分别为256、128、64、32、16、8、4、2、1、0.5和0.25μg/mL。
取无菌培养皿12个,1-12编号;无菌操作下,按相应的顺序将试管中的化合物(1)与培养基混合物倒入无菌培养皿中,静置冷却形成平板;各平板接种金黄色葡萄球菌;培养皿放入CO2细胞培养箱中,于37℃培养48h,测定化合物(1)的最低抑菌浓度(MIC值);同样方法测定化合物(1)抑制白色念珠菌、鲁西特念珠菌、克柔念珠菌、烟曲霉、土曲霉、隐球菌的MIC值;同样方法测定小檗碱、化合物(2)-(8)抑制金黄色葡萄球菌、白色念珠菌、鲁西特念珠菌、克柔念珠菌、烟曲霉、土曲霉、隐球菌的MIC值。
Claims (4)
1.一种小檗碱衍生物,其特征在于,具有如下通式:
,
式中,R各自独立为C6H13 , C8H17 , C12H25 , C4H9 , C3H7 , C2H5 , CH2C6H5, 。
2.根据权利要求1所述的一种小檗碱衍生物,其特征在于,代表实例结构式如下:
3.根据权利要求1所述的一种小檗碱衍生物,其特征在于,制备方法步骤如下:
,
式中,R各自独立为C6H13 , C8H17 , C12H25 , C4H9 , C3H7 , C2H5 , CH2C6H5, ;B各自独立为吡啶,Et3N。
4.根据权利要求1所述的一种小檗碱衍生物,其特征在于,在制备抗菌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310513482.XA CN116462675A (zh) | 2023-05-09 | 2023-05-09 | 一种小檗碱衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310513482.XA CN116462675A (zh) | 2023-05-09 | 2023-05-09 | 一种小檗碱衍生物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116462675A true CN116462675A (zh) | 2023-07-21 |
Family
ID=87184363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310513482.XA Pending CN116462675A (zh) | 2023-05-09 | 2023-05-09 | 一种小檗碱衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116462675A (zh) |
-
2023
- 2023-05-09 CN CN202310513482.XA patent/CN116462675A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2917305B2 (ja) | Fr−901155物質およびその生産法 | |
CN113087712B (zh) | L-氨基酸-6-胶霉毒素酯三氟乙酸盐及其制备方法 | |
US20080167463A1 (en) | Process for Preparation of Gemcitabine Hydrochloride | |
FI81357B (fi) | Foerfarande foer framstaellning av griseolinsyraderivat. | |
CN115650959A (zh) | 化合物的制备方法或纯化方法 | |
CN108218862B (zh) | α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用 | |
US20230312596A1 (en) | Method for large-scale synthesis of tetrodotoxin | |
CN116462675A (zh) | 一种小檗碱衍生物及其制备方法和应用 | |
CN103864638A (zh) | 一种苯甲酸类化合物及其制备方法和应用 | |
NO152840B (no) | Fremgangsmaate for fremstilling av dibenzyletere | |
JPS6310752A (ja) | トランス−4−シアノシクロヘキサン−1−カルボン酸の製造法 | |
CN101928310A (zh) | 3,2',6'-三-N-乙酰基庆大霉素C1a的制备方法 | |
CN115536674B (zh) | 一种哒嗪螺苯并磺内酰胺化合物及其合成方法与用途 | |
JP4334194B2 (ja) | エクチナサイジン786およびその取得方法 | |
JPH054069B2 (zh) | ||
CN108078993B (zh) | 6-硝基喹唑啉类化合物在制备治疗肺癌药物中的应用 | |
CN112321512A (zh) | 一种4,5-二碘-1h-咪唑的合成方法 | |
CN115286504A (zh) | 一种合成(r)-2-(2-(叔丁氧基)-2-氧乙基)戊酸的方法 | |
Uematsu et al. | 5-Hydroxymethyltubercidin. Synthesis, biological activity, and role in pyrrolopyrimidine biosynthesis | |
WO1988000198A1 (en) | Antitumor alkaloids | |
CN110698420A (zh) | 一种2-噁唑甲胺杂环化合物的制备方法 | |
KR820002099B1 (ko) | 치환 디벤질 에테르의 제조방법 | |
CN115141234A (zh) | 一种克林霉素磷酸酯原料药的合成工艺 | |
CN115716832A (zh) | 一种依鲁替尼杂质的制备方法及其应用 | |
CN110642922A (zh) | 一类甲硝唑接丝氨酸二肽化合物及其制备与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |